Latest From ViraTherapeutics GMBH
The head of the German family-owned firm's venture fund tells Scrip that investing very early in promising start-ups gives Boehringer Ingelheim "a little bit of a head start" on rival pharma companies in identifying technologies that could translate into therapies five years down the line .
Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.
Transgene's CEO discusses its immunotherapy pipeline, coming catalysts, and why the French biotech may soon be swept up by growing interest in oncolytic viruses.
Boehringer Ingelheim more than doubled its venture fund from €100m to €250m, giving BI more access to early innovation via new capital, two new investment managers and a West Coast presence.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- ViraTherapeutics GMBH
- Senior Management
Heinz Schwer, PhD, CEO
Lisa Egerer, PhD, COO
Dethardt Muller, PhD, Head of CMC
Patrik Erlmann, PhD, Head of R&D
Cedric Cheminay, PhD, Proj Manager, Preclinical Dev, Deputy Head R&D
- Contact Info
Phone: 512 272061
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.